ranibizumab

Paliperidone Palmitate is a long-acting injectable (LAI) formulation using nanocrystal technology. It is supplied as prefilled syringes requiring no refrigeration or reconstitution, offering once-monthly (1M) and three-monthly (3M) dosing options for schizophrenia, which significantly improves treatment ad...

Panitumumab is a fully human anti-EGFR mAb for RAS wild-type metastatic colorectal cancer. Its fully human sequence minimizes immunogenicity, with proven survival benefit in FOLFOX combination, representing a key precision therapy option in CRC.

Pegfilgrastim is a PEGylated long-acting G-CSF for chemotherapy-induced neutropenia prophylaxis. Its extended half-life reduces dosing from daily to once per chemotherapy cycle, minimizing treatment delays and serving as the benchmark in oncology supportive care.

Pembrolizumab is an anti-PD-1 mAb with the broadest approved indication portfolio globally. Spanning NSCLC first-line to MSI-H/TMB-H pan-tumor indications, it represents the absolute benchmark in immuno-oncology with an exceptionally high market ceiling.

Pertuzumab is an anti-HER2 mAb blocking HER2 dimerization with other HER family receptors. As a core component of dual-target therapy with trastuzumab in HER2+ breast cancer, it holds a firmly established position in high-value oncology segments.

Pertuzumab, trastuzumab, and hyaluronidase is a subcutaneous fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase. Replacing hours of IV infusion with 15-minute subcutaneous administration, it revolutionizes outpatient convenience and marks a milestone in breast cancer treatment delivery.

Risankizumab is an anti-IL-23 p19 mAb for psoriasis, Crohn's disease, and ulcerative colitis. With industry-leading PASI 90 response rates and q12w maintenance dosing, it offers exceptional compliance and ranks among the fastest-growing assets in immunology.

Romiplostim is a TPO receptor agonist peptibody for immune thrombocytopenia (ITP). As the standard second-line therapy with long-acting subcutaneous design, it remains effective in splenectomy-refractory patients, leading the hematology niche market.

Secukinumab is an anti-IL-17A mAb and the pathway leader in psoriasis, ankylosing spondylitis, and psoriatic arthritis. With industry-leading long-term PASI 100 clearance rates, it is a mature, high-volume immunology asset with stable market share.

Trastuzumab deruxtecan is a HER2-directed ADC that pioneered therapy for HER2-low breast cancer. The DESTINY program has reshaped global guidelines, with massive cross-tumor potential across breast, gastric, and lung cancers, setting the ADC technology benchmark.

Vedolizumab is an anti-α4β7 integrin mAb for ulcerative colitis and Crohn's disease. Its gut-selective anti-lymphocyte trafficking mechanism avoids systemic immunosuppression and PML risk, making it the preferred safety option among IBD biologics.

Abaloparatide is a PTHrP(1-34) analog acting as an agonist at the PTH1 receptor (PTH1R). It activates the cAMP signaling pathway to stimulate osteoblastic activity and new bone formation. Administered as 80 mcg subcutaneously once daily. Abaloparatide demonstrates rapid and robust bone formation with the b...